Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Stock query: Sanofi India in a sideways phase
Inability to move beyond 8,500 can keep it range-bound between 7,500 and 8,500 Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi under investigation on charges including manslaughter over Depakine
Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine European Union in talks to secure Sanofi deal for coronavirus vaccine
Armed with an emergency fund of more than 2 billion euros (1.80 billion pounds), the European Commission wants to strike deals with up to six drug makers for their vaccines Sanofi India: Sturdy balance sheet, cash-generation augur well for company
High growth visibility in chronics, low exposure to regulated markets and strong balance sheet will help sustain premium valuation Sanofi lifts earnings view as Regeneron stake sale boosts second quarter
Sanofi is working on two of the more than 150 potential Covid-19 vaccines being developed across the world Sanofi India Ltd - 500674 - Appointment Of Directors
The Board of Directors of the Company at its Meeting held today, based on recommendation of the Nomination and Remuneration Committee approved the appointment of the following Directors: 1. Mr. Rahul Bhatnagar (DIN 07268064) as Additional Director (Non-Executive & Independent) of the Company with effect from 29th July 2020 to hold office till the conclusion of the next Annual General Meeting and subject to the approval of the members in the ensuing General Meeting, for appointment as an Independent Director for a term of five consecutive years from the effective date of this appointment. 2. Mr. Marc-Antoine Lucchini (DIN 08812302) as Additional Director (Non-Executive) with effect from 29th July 2020 to hold office up to the date of next Annual General Meeting of the Company. Sanofi India Ltd - 500674 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2020
We refer to our letter dated 15th July 2020 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.30 a.m. and concluded at 3.25 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2020. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2020 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2020 along with a copy of the Limited Review Report duly signed by the Auditors of the Company. Please take the above information on record. Sanofi India Ltd - 500674 - Disclosure On Impact Of The COVID-19 Pandemic
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/ 2020/84 dated 20th May 2020, please find enclosed a summary of the impact of the COVID-19 Pandemic on the business and operations of the Company.